These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15617327)

  • 1. [Management of communal lower respiratory tract infections in the emergency ward: the role of Ketek (telithromycine)].
    Dubreuil L; Elkharrat D; Bru JP
    Med Mal Infect; 2004 Jan; 34(1):51-6. PubMed ID: 15617327
    [No Abstract]   [Full Text] [Related]  

  • 2. The evolution of antimicrobial agents used for the management of CARTIs: a focus on a new class of antimicrobials--the ketolides.
    Sbarbaro JA
    Am J Manag Care; 2004 Oct; 10(12 Suppl):S389-99. PubMed ID: 15603248
    [No Abstract]   [Full Text] [Related]  

  • 3. Telithromycin (Ketek) for respiratory infections.
    Med Lett Drugs Ther; 2004 Aug; 46(1189):66-8. PubMed ID: 15314586
    [No Abstract]   [Full Text] [Related]  

  • 4. Telithromycin: do we really need this antimicrobial?
    Fish DN
    Am J Health Syst Pharm; 2005 May; 62(9):901. PubMed ID: 15851495
    [No Abstract]   [Full Text] [Related]  

  • 5. Telithromycin--a ketolide antibiotic for the treatment of outpatients with community-acquired respiratory tract infections.
    Counts M
    Clin Nurse Spec; 2005; 19(3):121-3. PubMed ID: 15897765
    [No Abstract]   [Full Text] [Related]  

  • 6. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
    Carter PL
    Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic outcomes in the treatment of lower respiratory tract infections.
    Brixner DI
    Am J Manag Care; 2004 Oct; 10(12 Suppl):S400-7. PubMed ID: 15603249
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of ketolides on resistance selection and ecologic effects during treatment for respiratory tract infections.
    Nord CE; Farrell DJ; Leclercq R
    Microb Drug Resist; 2004; 10(3):255-63. PubMed ID: 15383171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Telithromycin in the management of lower respiratory tract infections in the hospital].
    Léophonte P
    Presse Med; 2003 Jun; 32(20):952-3. PubMed ID: 12876542
    [No Abstract]   [Full Text] [Related]  

  • 10. Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections.
    Van Bambeke F; Harms JM; Van Laethem Y; Tulkens PM
    Expert Opin Pharmacother; 2008 Feb; 9(2):267-83. PubMed ID: 18201149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Importance in respiratory tract infections. Ketolides: clinical aspects].
    Lorenz J; Steiert P
    Pharm Unserer Zeit; 2004; 33(1):42-6. PubMed ID: 14968712
    [No Abstract]   [Full Text] [Related]  

  • 12. Telithromycin.
    Spiers KM; Zervos MJ
    Expert Rev Anti Infect Ther; 2004 Oct; 2(5):685-93. PubMed ID: 15482232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and antibacterial activity of 6-O-arylpropargyl-9-oxime-11,12-carbamate ketolides.
    Beebe X; Yang F; Bui MH; Mitten MJ; Ma Z; Nilius AM; Djuric SW
    Bioorg Med Chem Lett; 2004 May; 14(10):2417-21. PubMed ID: 15109624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections.
    Hammerschlag MR; Sharma R
    Expert Opin Investig Drugs; 2008 Mar; 17(3):387-400. PubMed ID: 18321237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telithromycin (Ketek) for community-acquired respiratory tract infections.
    Wimett L; Laustsen G
    Nurse Pract; 2004 Sep; 29(9):56-60. PubMed ID: 15359148
    [No Abstract]   [Full Text] [Related]  

  • 16. Recent findings from multinational resistance surveys: are we 'PROTEKTed' from resistance?
    Marchese A; Schito GC
    Int J Antimicrob Agents; 2007 Feb; 29 Suppl 1():S2-5. PubMed ID: 17307653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction: PROTEKT against respiratory tract infection.
    Stratton CW
    J Chemother; 2002 Jul; 14 Suppl 3():5-8. PubMed ID: 12418555
    [No Abstract]   [Full Text] [Related]  

  • 18. Limit Ketek to pneumonia, experts advise: advisers urge black-box warning.
    Young D
    Am J Health Syst Pharm; 2007 Jan; 64(2):124-5. PubMed ID: 17215452
    [No Abstract]   [Full Text] [Related]  

  • 19. Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting.
    Clark JP; Langston E
    Mayo Clin Proc; 2003 Sep; 78(9):1113-24. PubMed ID: 12962166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bacterial airway infections. Standard antibiotics more often ineffective].
    MMW Fortschr Med; 2002 Feb; 144(8):52. PubMed ID: 11910829
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.